Free Trial
NASDAQ:SNPX

Synaptogenix (SNPX) Stock Price, News & Analysis

Synaptogenix logo
$2.56 -0.12 (-4.31%)
As of 03/28/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Synaptogenix Stock (NASDAQ:SNPX)

Key Stats

Today's Range
$2.48
$2.78
50-Day Range
$2.57
$3.53
52-Week Range
$2.15
$6.22
Volume
17,592 shs
Average Volume
31,208 shs
Market Capitalization
$3.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00
Consensus Rating
Buy

Company Overview

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

Remove Ads

Synaptogenix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

SNPX MarketRank™: 

Synaptogenix scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Synaptogenix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Synaptogenix has received no research coverage in the past 90 days.

  • Read more about Synaptogenix's stock forecast and price target.
  • Percentage of Shares Shorted

    1.45% of the float of Synaptogenix has been sold short.
  • Short Interest Ratio / Days to Cover

    Synaptogenix has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Synaptogenix has recently decreased by 11.47%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Synaptogenix does not currently pay a dividend.

  • Dividend Growth

    Synaptogenix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.45% of the float of Synaptogenix has been sold short.
  • Short Interest Ratio / Days to Cover

    Synaptogenix has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Synaptogenix has recently decreased by 11.47%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Synaptogenix has a news sentiment score of -0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Synaptogenix this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Synaptogenix insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.73% of the stock of Synaptogenix is held by insiders.

  • Percentage Held by Institutions

    Only 10.34% of the stock of Synaptogenix is held by institutions.

  • Read more about Synaptogenix's insider trading history.
Receive SNPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synaptogenix and its competitors with MarketBeat's FREE daily newsletter.

SNPX Stock News Headlines

Synaptogenix Inc Ordinary Shares
Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
Synaptogenix Announces $5.0 Million Financing
See More Headlines

SNPX Stock Analysis - Frequently Asked Questions

Synaptogenix's stock was trading at $3.47 on January 1st, 2025. Since then, SNPX shares have decreased by 22.8% and is now trading at $2.68.
View the best growth stocks for 2025 here
.

Synaptogenix, Inc. (NASDAQ:SNPX) issued its earnings results on Thursday, March, 27th. The company reported ($4.36) earnings per share for the quarter, missing analysts' consensus estimates of ($2.06) by $2.30.

Shares of Synaptogenix reverse split on the morning of Friday, April 5th 2024. The 1-25 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Top institutional shareholders of Synaptogenix include Geode Capital Management LLC (0.80%). Insiders that own company stock include Daniel L Alkon and William S Singer.
View institutional ownership trends
.

Shares of SNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Synaptogenix investors own include SoFi Technologies (SOFI), Fluence Energy (FLNC), The9 (NCTY), Riot Platforms (RIOT), PubMatic (PUBM), Clean Energy Fuels (CLNE) and FuelCell Energy (FCEL).

Company Calendar

Last Earnings
3/27/2025
Today
3/29/2025
Next Earnings (Estimated)
4/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SNPX
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$14.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+422.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$25.27 per share
Price / Book
0.11

Miscellaneous

Free Float
1,319,000
Market Cap
$3.63 million
Optionable
Not Optionable
Beta
1.10
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:SNPX) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners